Dataset Information


RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).

ABSTRACT: Ral (Ras like) leads an important proto-oncogenic signaling pathway down-stream of Ras. In this work, RalA was found to be significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues as compared to non-malignant samples. Other elements of RalA pathway such as RalBP1 and RalGDS were also expressed at higher levels in malignant samples. Inhibition of RalA by gene-specific silencing caused a robust decrease in the viability and invasiveness of HCC cells. Additionally, the use of geranyl-geranyl transferase inhibitor (GGTI, an inhibitor of Ral activation) and Aurora kinase inhibitor II resulted in a significant decrease in the proliferation of HCC cells. Furthermore, RalA activation was found to be at a higher level of activation in HCC stem cells that express CD133. Transgenic mouse model for HCC (FXR-Knockout) also revealed an elevated level of RalA-GTP in the liver tumors as compared to background animals. Finally, subcutaneous mouse model for HCC confirmed effectiveness of inhibition of aurora kinase/RalA pathway in reducing the tumorigenesis of HCC cells in vivo. In conclusion, RalA overactivation is an important determinant of malignant phenotype in differentiated and stem cells of HCC and can be considered as a target for therapeutic intervention.

SUBMITTER: Ezzeldin M 

PROVIDER: S-EPMC5528517 | BioStudies | 2014-01-01

SECONDARY ACCESSION(S): 10.1016/j.molonc.2014.03.020

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6605813 | BioStudies
2016-01-01 | S-EPMC4991475 | BioStudies
2010-01-01 | S-EPMC2803332 | BioStudies
2020-01-01 | S-EPMC7132301 | BioStudies
2014-01-01 | S-EPMC3910332 | BioStudies
1000-01-01 | S-EPMC420081 | BioStudies
1000-01-01 | S-EPMC4973806 | BioStudies
2019-01-01 | S-EPMC6459002 | BioStudies
1000-01-01 | S-EPMC2798468 | BioStudies
2005-01-01 | S-EPMC544910 | BioStudies